CA
NZ
UK
AU
IND
US
NovoCure Limited (NASDAQ: NVCR) has drawn a varied response from analysts, as its stock continues to trade at a discount compared to its 52-week high. On Tuesday, MarketBeat Ratings reported that LADENBURG THALM/SH SH reiterated a “Buy” rating for the medical equipment company and …
Haleon (LSE/NYSE: HLN) has broken ground on its newGBP130 million Global Oral Health Innovation Centrein Weybridge, Surrey. The project marks a significant step in the company’s expansion of its oral health research and development infrastructure. Once completed, the centre will act as a hub …
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced the publication of new discoveries featured on the cover ofScience. The article,“Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition,”presents how Monte Rosa’s AI and machine learning engine uncovered a broad range of human …
Mesoblast (Nasdaq: MESO; ASX: MSB)announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on key components required to file a Biologics License Application (BLA) for its cell therapy candidate Revascor® (rexlemestrocel-L) for the treatment of ischemic heart failure with …
BofA Securities issued a notable downgrade forProKidney Corp. (NASDAQ: PROK)on Monday, shifting its rating fromNeutraltoUnderperformand sharply reducing its price target from USD3.00 to USD1.00 per share. The reassessment follows a combination of revised expectations for ProKidney’s lone therapeutic candidate, REACT, and growing caution regarding …
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company focused on programmed T cell therapies, has announced updated results from its ongoing FELIX trial evaluating obe-cel, an autologous CD19 CAR T-cell therapy, in adults with relapsed or refractory (r/r) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced updates related to its Founded Entity, Vor Bio (Nasdaq: VOR), following two major financial transactions. Vor Bio has entered an exclusive global license agreement with RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331), excluding China, Hong Kong, …
Evotec SE (Frankfurt Stock Exchange: EVT; Nasdaq: EVO) has announced its participation in the NURTuRE-AKI consortium, a longitudinal research initiative focused on acute kidney injury (AKI) and its progression to chronic kidney disease (CKD). The study targets both adult and pediatric cardiac surgery patients …
InspireMD, Inc. (Nasdaq: NSPR), a medical technology company focused on stroke prevention, has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for its CGuard Prime Carotid Stent System. The approval allows the commercial launch of the device in the U.S. …
argenx SE (Euronext & Nasdaq: ARGX)is a biopharmaceutical company focused on the development of antibody-based treatments for severe autoimmune diseases. Through collaborations with academic researchers, argenx aims to build a portfolio of immune-mediated therapies. The company is advancing its FcRn blocker, efgartigimod, across multiple …
Please wait processing your request...